Answer
Nimenrix is indicated from 6 weeks of age for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y.
Sources for this answer
- Nimenrix powder and solvent for solution for injection in pre-filled syringePfizer Limited · emc · SmPC §4.1 Therapeutic Indications · Version 34Document updated
Sources checked